{"id":"duration-of-dapt","safety":{"commonSideEffects":[{"rate":null,"effect":"Stent thrombosis (if DAPT discontinued prematurely)"},{"rate":null,"effect":"Bleeding complications (if DAPT prolonged)"},{"rate":null,"effect":"Recurrent myocardial infarction"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"DAPT duration is a clinical management strategy rather than a drug itself, determining how long patients should continue dual antiplatelet therapy to balance the reduction of stent thrombosis and atherosclerotic events against the risk of bleeding complications. The optimal duration varies based on clinical presentation (acute coronary syndrome vs. stable coronary artery disease), stent type (bare-metal vs. drug-eluting), and individual patient bleeding risk. Samsung Medical Center's work in this area likely involves clinical research or guidelines on DAPT duration optimization.","oneSentence":"Duration of DAPT refers to the optimal length of time a patient should remain on dual antiplatelet therapy (typically aspirin plus a P2Y12 inhibitor) following percutaneous coronary intervention.","_ai_confidence":"low"},"_scrapedAt":"2026-03-27T23:45:09.725Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Optimization of dual antiplatelet therapy duration following percutaneous coronary intervention with stent placement"}]},"trialDetails":[{"nctId":"NCT06521463","phase":"NA","title":"SIMPLAAFY Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Boston Scientific Corporation","startDate":"2024-10-01","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":1857},{"nctId":"NCT07391358","phase":"NA","title":"DAPT Strategy in HBR Patients Undergoing Complex PCI Following ACS: Second-Phase Beta Testing of a Patients Decision Aid","status":"NOT_YET_RECRUITING","sponsor":"Montreal Heart Institute","startDate":"2026-02-01","conditions":"Acute Coronary Syndrome","enrollment":26},{"nctId":"NCT07379190","phase":"PHASE3","title":"HR-MRI-Directed Tirofiban Therapy for Late-Window Acute Ischemic Stroke (TIAN)","status":"NOT_YET_RECRUITING","sponsor":"Weifang Medical University","startDate":"2026-02-01","conditions":"Stroke, Acute, Stroke, Ischemic, Cerebral Infarction","enrollment":458},{"nctId":"NCT05785897","phase":"NA","title":"STEMI Treated With a Polymer-free Sirolimus-coated Stent and P2Y12 Inhibitor-based SAPT Versus Conventional DAPT","status":"RECRUITING","sponsor":"IGLESIAS Juan Fernando","startDate":"2025-11-01","conditions":"ST Elevation Myocardial Infarction","enrollment":350},{"nctId":"NCT06535568","phase":"NA","title":"Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)","status":"RECRUITING","sponsor":"Fondazione Ricerca e Innovazione Cardiovascolare ETS","startDate":"2026-01-10","conditions":"Coronary Disease, Heart Diseases, Cardiovascular Diseases","enrollment":576},{"nctId":"NCT07198529","phase":"NA","title":"OCT-Guided Stent Optimization for Short-Duration Dual Antiplatelet Therapy in Stable Angina","status":"RECRUITING","sponsor":"Korea University Guro Hospital","startDate":"2025-09-30","conditions":"Stable Angina, Coronary Artery Disease","enrollment":130},{"nctId":"NCT06742931","phase":"NA","title":"Drug-Coated Balloon Versus Drug-Eluting Stent for Treatment of De-Novo Coronary Lesions in Patients With High Bleeding Risk-2","status":"RECRUITING","sponsor":"Samsung Medical Center","startDate":"2025-04-07","conditions":"Chronic Coronary Syndrome","enrollment":1200},{"nctId":"NCT07164859","phase":"PHASE3","title":"Safety and Efficacy of Very Short DAPT in Older Patients Undergoing PCI","status":"NOT_YET_RECRUITING","sponsor":"Vincent ROULE","startDate":"2025-10","conditions":"Coronary Artery Disease (CAD), Percutaneous Coronary Intervention (PCI), Antiplatelet Therapy","enrollment":1700},{"nctId":"NCT05732701","phase":"NA","title":"Algorithm-based Tailoring of Dual Antiplatelet Therapy to Improve Outcomes Following Percutaneous Coronary Interventions","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2023-06-27","conditions":"Percutaneous Coronary Intervention, Platelet Aggregation Inhibitors, Coronary Artery Disease","enrollment":2788},{"nctId":"NCT06216821","phase":"NA","title":"OPT-CAD Score GUIded Dual ANtiplatelet De-esCalation Time","status":"RECRUITING","sponsor":"Shenyang Northern Hospital","startDate":"2024-07-02","conditions":"Acute Coronary Syndrome","enrollment":3490},{"nctId":"NCT05631769","phase":"PHASE4","title":"HOST - DAPT Duration According the Bleeding Risk","status":"ACTIVE_NOT_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2020-07-24","conditions":"Coronary Artery Disease, Acute Myocardial Infarction, Stable Angina","enrollment":4900},{"nctId":"NCT07024446","phase":"","title":"Comparison of Cardiovascular Risks Between Hip Fracture Surgery With Continued DAPT（Dual Antiplatelet Therapy ） Within 6 Weeks vs After 6 Weeks Post-PCI（Percutaneous Coronary Intervention）: A Prospective Observational Cohort Study","status":"NOT_YET_RECRUITING","sponsor":"Fujian Medical University Union Hospital","startDate":"2025-07-01","conditions":"PCI Patients, DAPT(Dual Antiplatelet Therapy), Hip Fracture Surgeries","enrollment":50},{"nctId":"NCT05066789","phase":"PHASE4","title":"CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 4","status":"TERMINATED","sponsor":"Samsung Medical Center","startDate":"2022-01-17","conditions":"Coronary Artery Disease","enrollment":100},{"nctId":"NCT05952206","phase":"PHASE3","title":"Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy","status":"RECRUITING","sponsor":"iVascular S.L.U.","startDate":"2023-10-13","conditions":"Coronary Artery Disease","enrollment":2312},{"nctId":"NCT06943586","phase":"NA","title":"Pharmacogenomics in Stroke: Feasibility of CYP2C19 Testing","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-04-09","conditions":"Stroke, Transient Ischemic Attack (TIA)","enrollment":200},{"nctId":"NCT06718179","phase":"PHASE4","title":"Comparison of Short Versus 12 Months Prasugrel Plus Aspirin in Patients with Acute Coronary Syndromes Treated with Percutaneous Coronary Intervention and Everolimus-eluting Stents","status":"RECRUITING","sponsor":"Odense University Hospital","startDate":"2024-11-16","conditions":"Acute Coronary Syndrome","enrollment":3150},{"nctId":"NCT06075433","phase":"","title":"Efficacy and Safety of 1-year Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease According to the Complex Higher-risk Procedure","status":"RECRUITING","sponsor":"Genoss Co., Ltd.","startDate":"2022-05-13","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy","enrollment":1000},{"nctId":"NCT06075420","phase":"","title":"Efficacy and Safety of Short Duration of DAPT After GENOSS® DES Implantation in Patients with Coronary Artery Disease","status":"RECRUITING","sponsor":"Genoss Co., Ltd.","startDate":"2021-08-18","conditions":"Percutaneous Coronary Intervention, Dual Antiplatelet Therapy","enrollment":1000},{"nctId":"NCT03805048","phase":"NA","title":"PeRcutaneous cOronary Intervention of Native Coronary arTery Versus Venous Bypass Graft in Patients With Prior CABG","status":"ACTIVE_NOT_RECRUITING","sponsor":"Amsterdam UMC, location VUmc","startDate":"2019-01-22","conditions":"Coronary Artery Disease","enrollment":221},{"nctId":"NCT04418479","phase":"PHASE4","title":"SMart Angioplasty Research Team: CHoice of Optimal Anti-Thrombotic Strategy in Patients Undergoing Implantation of Coronary Drug-Eluting Stents 3","status":"COMPLETED","sponsor":"Joo-Yong Hahn","startDate":"2020-08-10","conditions":"Coronary Artery Disease","enrollment":5506},{"nctId":"NCT06683300","phase":"","title":"Drug Eluting Stenting and Short Dual Antiplatelet Therapy for Preventing Recurrent Stroke in Vertebral Stenosis Registry Study","status":"NOT_YET_RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2024-11","conditions":"Vertebral Artery Stenosis","enrollment":520},{"nctId":"NCT06648720","phase":"NA","title":"Efficacy and Safety of Shortening Dual Antiplatelet Therapy Duration with IVUS Guidance in PCI Patients","status":"NOT_YET_RECRUITING","sponsor":"University Medical Center Ho Chi Minh City (UMC)","startDate":"2025-03-01","conditions":"Coronary Arterial Disease (CAD), Percutaneous Coronary Intervention (PCI), Intravascular Ultrasound","enrollment":3566},{"nctId":"NCT05122780","phase":"PHASE4","title":"Prognostic Value of Precision Medicine in Patients With MINOCA (PROMISE Trial).","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","startDate":"2021-07-01","conditions":"Myocardial Infarction With Non-Obstructive Coronary Arteries","enrollment":120},{"nctId":"NCT02939872","phase":"PHASE4","title":"Optimal Duration of Antiplatelet Therapy After Bioresorbable Vascular Scaffold Implantation to Reduce Late Coronary Arterial Thrombotic Events","status":"COMPLETED","sponsor":"Seung-Jung Park","startDate":"2017-03-09","conditions":"Percutaneous Transluminal Coronary Angioplasty, Coronary Disease","enrollment":238},{"nctId":"NCT02619760","phase":"PHASE4","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study","status":"COMPLETED","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2015-12","conditions":"Coronary Artery Disease","enrollment":3045},{"nctId":"NCT04609111","phase":"PHASE4","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-3 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2021-01-29","conditions":"Acute Coronary Syndrome","enrollment":6002},{"nctId":"NCT03462498","phase":"PHASE4","title":"ShorT and OPtimal Duration of Dual AntiPlatelet Therapy-2 Study for the Patients With ACS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Kyoto University, Graduate School of Medicine","startDate":"2018-04-02","conditions":"Acute Coronary Syndrome, Acute Myocardial Infarction, Coronary Artery Disease","enrollment":3008},{"nctId":"NCT05204212","phase":"NA","title":"Left Atrial Appendage Closure in Patients With Non-valvular Atrial Fibrillation and End-stage Chronic KIDNEY Disease","status":"RECRUITING","sponsor":"Prof. Dr. med. Ingo Eitel","startDate":"2022-03-28","conditions":"Non-valvular Atrial Fibrillation (NVAF): Paroxysmal, Persistent, Permanent","enrollment":430},{"nctId":"NCT05262803","phase":"PHASE4","title":"Reduced Antithrombotic Strategy for High Bleeding Risk Patients With Myocardial Infarction","status":"RECRUITING","sponsor":"Rikke Sorensen","startDate":"2022-06-17","conditions":"Myocardial Infarction","enrollment":2808},{"nctId":"NCT06301776","phase":"NA","title":"A Prospective, Experimental, Multicenter, Open-label, Randomized, Controlled Trial of 3-month Dual Antiplatelet Therapy Followed by Ticagrelor Versus 6-month Dual Antiplatelet Therapy Followed by Ticagrelor After Implanting Bridge","status":"RECRUITING","sponsor":"The Fourth Affiliated Hospital of China Medical University","startDate":"2023-12-05","conditions":"Brain Disease, Vertebral Artery Stenosis","enrollment":560},{"nctId":"NCT04135989","phase":"PHASE4","title":"Personalized Vs. Standard Duration of Dual Antiplatelet Therapy and New-generation Polymer-Free vs- Biodegradable-Polymer DES","status":"UNKNOWN","sponsor":"Federico II University","startDate":"2020-01-01","conditions":"Coronary Artery Disease, Acute Coronary Syndrome, Chronic Coronary Syndrome","enrollment":2106},{"nctId":"NCT02099617","phase":"NA","title":"Efficacy and Safety of New Generation Drug Eluting Stents Associated With an Ultra Short Duration of Dual Antiplatelet Therapy. Design of the Short Duration of Dual antiplatElet Therapy With SyNergy II Stent in Patients Older Than 75 Years Undergoing Percutaneous Coronary Revascularization.","status":"COMPLETED","sponsor":"Ceric Sàrl","startDate":"2014-05","conditions":"Stable Angina, Silent Myocardial Ischemia, Acute Coronary Syndrome","enrollment":1200},{"nctId":"NCT06084000","phase":"NA","title":"STrategies of Scheduled Drug-coated Balloons (DCB) Versus Conventional DES for the interveNTional Therapy of de Novo Lesions in Large Coronary vESSels (STENTLESS) Trial","status":"UNKNOWN","sponsor":"China National Center for Cardiovascular Diseases","startDate":"2023-10-15","conditions":"Drug-coated Balloon, Drug-eluting Stent, De Novo Stenosis","enrollment":2700},{"nctId":"NCT05936606","phase":"NA","title":"Tailored Anti-platelet Therapy After DES Implantation in High-risk Patients","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-08-16","conditions":"Coronary Artery Disease","enrollment":3434},{"nctId":"NCT03908593","phase":"PHASE4","title":"Proton Pump Inhibitor Preventing Upper Gastrointestinal Injury In Patients On Dual Antiplatelet Therapy After CABG","status":"UNKNOWN","sponsor":"Ruijin Hospital","startDate":"2019-10-14","conditions":"Gastrointestinal Ulcer (Peptic) or Erosion, Anti-Platelet Therapy, Coronary Artery Bypass","enrollment":232},{"nctId":"NCT04135677","phase":"PHASE4","title":"Clinical Outcomes Between Anticoagulation and DAPT Therapy in AF Patients Successfully Undergoing LAAO","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2022-11-11","conditions":"Left Atrial Appendage Thrombosis, Thrombi, Stroke","enrollment":826},{"nctId":"NCT05487560","phase":"","title":"An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding","status":"COMPLETED","sponsor":"Hanmi Pharmaceutical Company Limited","startDate":"2019-04-18","conditions":"Acute Coronary Syndrome or B Cerebral Infarction Requiring DAPT(Clopidogrel + Aspirin) for at Least 6 Months","enrollment":4133},{"nctId":"NCT03198741","phase":"PHASE4","title":"Mono- Versus Dual antiPlatelet Therapy During 6-12 Months After New Generation Drug Eluting Stent Implantation","status":"COMPLETED","sponsor":"Shenyang Northern Hospital","startDate":"2017-07-13","conditions":"Gastrointestinal Injury, Ischemic Heart Disease","enrollment":783},{"nctId":"NCT03877848","phase":"","title":"EluNIR Ridaforolimus Eluting Coronary Stent System in Patients at High Bleeding Risk (HBR)- EluNIR HBR Study","status":"COMPLETED","sponsor":"Medinol Ltd.","startDate":"2019-05-06","conditions":"Coronary Stenosis","enrollment":319},{"nctId":"NCT03023020","phase":"NA","title":"Management of High Bleeding Risk Patients Post Bioresorbable Polymer Coated Stent Implantation With an Abbreviated Versus Prolonged DAPT Regimen","status":"COMPLETED","sponsor":"ECRI bv","startDate":"2017-04-04","conditions":"High Bleeding Risk, Coronary Artery Disease, PCI","enrollment":4579},{"nctId":"NCT04999293","phase":"","title":"Ticagrelor in Elderly Patients Undergoing Percutaneous Coronary Intervention","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Dalian Medical University","startDate":"2021-07-20","conditions":"Platelet Aggregation Inhibitors, Dual Anti-Platelet Therapy, Aged","enrollment":1505},{"nctId":"NCT03355742","phase":"NA","title":"XIENCE 28 Global Study","status":"COMPLETED","sponsor":"Abbott Medical Devices","startDate":"2018-02-09","conditions":"Bleeding Disorder, Stroke, Ischemic, Stroke Hemorrhagic","enrollment":963},{"nctId":"NCT02217501","phase":"PHASE3","title":"Antiplatelet Strategy for Peripheral Arterial Interventions for Revascularization of Lower Extremities","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2015-11","conditions":"Peripheral Arterial Disease","enrollment":159},{"nctId":"NCT02594501","phase":"NA","title":"Randomized Trial of COBRA PzF Stenting to Reduce Duration of Triple Therapy","status":"UNKNOWN","sponsor":"CeloNova BioSciences, Inc.","startDate":"2016-02-05","conditions":"Angina, Stable, Angina, Unstable, Anticoagulants","enrollment":996},{"nctId":"NCT00963781","phase":"PHASE4","title":"Scripps Evaluation of Antiplatelet Therapies for Intermediate Duration With the Endeavor Stent (Seaside)","status":"COMPLETED","sponsor":"Scripps Health","startDate":"2009-08","conditions":"Coronary Artery Disease, Coronary Thrombosis","enrollment":219},{"nctId":"NCT02513810","phase":"NA","title":"A Randomized Controlled Comparison Between One Versus More Than Six Months of Dual Antiplatelet Therapy After Biolimus A9-eluting Stent Implantation","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2015-12-02","conditions":"Coronary Artery Disease","enrollment":3020},{"nctId":"NCT03112707","phase":"PHASE4","title":"Bioresorbable Polymer-Coated EES in Patients at High Bleeding Risk Undergoing PCI Followed by 1-Month DAPT","status":"UNKNOWN","sponsor":"Humanitas Hospital, Italy","startDate":"2017-04-14","conditions":"Coronary Artery Disease, Acute Coronary Syndrome","enrollment":1023},{"nctId":"NCT03038009","phase":"PHASE4","title":"Proton Pump Inhibitor Prevent Dual Antiplatelet Agents Induced Gastrointestinal Ulcer After Coronary Artery Bypass Graft","status":"WITHDRAWN","sponsor":"Ruijin Hospital","startDate":"2018-10","conditions":"Gastric Ulcer Induced by Antiplatelet Agent, Ulcer of the Gastrointestinal Tract, Proton Pump Inhibitor","enrollment":""},{"nctId":"NCT01752894","phase":"NA","title":"DETErmination of the Duration of the Dual Antiplatelet Therapy by the Degree of the Coverage of The Struts on Optical Coherence Tomography From the Randomized Comparison Between Everolimus-eluting Stents(EES) Versus Biolimus A9-eluting Stents(BES)","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2013-01-02","conditions":"Ischemic Heart Disease","enrollment":776},{"nctId":"NCT03338335","phase":"","title":"Ethnic Differences and the Ischemia/Bleeding Risk of DAPT Duration","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2017-03-01","conditions":"Coronary Artery Disease, Percutaneous Coronary Intervention, Dual Antiplatelet Therapy","enrollment":16000},{"nctId":"NCT01701453","phase":"NA","title":"Safety of 6-month Duration of Dual Antiplatelet Therapy After Acute Coronary Syndromes (SMART-DATE)","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2012-08","conditions":"Acute Coronary Syndrome","enrollment":2712},{"nctId":"NCT01514227","phase":"PHASE4","title":"Nobori Dual Antiplatelet Therapy as Appropriate Duration","status":"COMPLETED","sponsor":"Associations for Establishment of Evidence in Interventions","startDate":"2011-12","conditions":"Coronary Artery Disease","enrollment":3773},{"nctId":"NCT01325935","phase":"PHASE4","title":"Optimal Duration of DAPT Following Treatment With Endeavor (Zotarolimus-eluting Stent) in Real-world Japanese Patients","status":"COMPLETED","sponsor":"Associations for Establishment of Evidence in Interventions","startDate":"2011-04","conditions":"Coronary Artery Disease","enrollment":1187},{"nctId":"NCT01113372","phase":"PHASE4","title":"Optimized Duration of Clopidogrel Therapy Following Treatment With the Endeavor - Optimize Trial","status":"COMPLETED","sponsor":"Cardiovascular Research Center, Brazil","startDate":"2010-04","conditions":"Coronary Artery Disease","enrollment":3119},{"nctId":"NCT02303717","phase":"NA","title":"Xience Versus Synergy in Left Main PCI","status":"UNKNOWN","sponsor":"NHS National Waiting Times Centre Board","startDate":"2014-12","conditions":"Coronary Artery Disease","enrollment":818},{"nctId":"NCT00954707","phase":"PHASE4","title":"CYPRESS - CYPHER for Evaluating Sustained Safety","status":"UNKNOWN","sponsor":"Cordis US Corp.","startDate":"2009-08","conditions":"Coronary Artery Disease","enrollment":2509},{"nctId":"NCT01385319","phase":"PHASE3","title":"Zotarolimus-eluting Endeavor Sprint Stent in Uncertain DES Candidates (ZEUS) Study","status":"UNKNOWN","sponsor":"Marco Valgimigli","startDate":"2011-06","conditions":"Coronary Artery Disease","enrollment":1606}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Duration of DAPT","genericName":"Duration of DAPT","companyName":"Samsung Medical Center","companyId":"samsung-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Duration of DAPT refers to the optimal length of time a patient should remain on dual antiplatelet therapy (typically aspirin plus a P2Y12 inhibitor) following percutaneous coronary intervention. Used for Optimization of dual antiplatelet therapy duration following percutaneous coronary intervention with stent placement.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}